Manufacture

When following COVID-19 research, it’s hard to keep your eye on the ball...

How can we best deliver solubility-challenged small molecules to the clinic?

The gene and cell therapy market is growing, but does it have the CDMO support needed to maintain its upward trajectory?

A vaccine must be able to reach patients who need it. Reliable partners and procedures are a must.

Introducing the fourth therapeutic class: live biotherapeutics – microorganisms isolated from the human gut with the potential to treat many diseases.

Global access to the vaccine is essential to provide protection against the virus. A big hurdle to accessibility will likely be price.

Most clinical trials against COVID-19 exclude the very patients most at risk from the disease.

Nominate the top pharmaceutical technologies in our 2020 Innovation Awards.

A typical vaccine takes around 10 to 12 years to reach the market. A key question: “Where should we base production?”

SCHOTT introduces an online shop with low minimum order quantities to overcome the challenges associated with conventional purchase order procedures.